Marcy-L'Etoile, France - March 16, 2009. The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, March 13 to approve the consolidated financial statements for the year ended December 31, 2008. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors.
- Strong sales growth: +9.8%, at constant exchange rates, including business development
- Improved operating margin before non recurring-items at 16.8% of sales
- Substantial R&D and manufacturing investments
- Three strategic acquisitions and expansion of international network